Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

(2013) Alessandro Liberati   ANNALS OF INTERNAL MEDICINE

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

(2013) John B. Buse et al.   ANNALS OF INTERNAL MEDICINE

Ethnic Differences in the Relationship Between Insulin Sensitivity and Insulin Response: A systematic review and meta-analysis

(2013) K. Kodama et al.   DIABETES CARE

Once weekly exenatide: efficacy, tolerability and place in therapy

(2013) C. Wysham et al.   DIABETES OBESITY & METABOLISM

Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

(2013) Y. G. Kim et al.   DIABETOLOGIA

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

(2013) Carolyn F Deacon et al.   EXPERT OPINION ON PHARMACOTHERAPY

Clinical Characteristics of the Responders to Dipeptidyl Peptidase-4 Inhibitors in Korean Subjects with Type 2 Diabetes

(2013) Tae Jung Oh et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis

(2012) Haesuk Park et al.   ANNALS OF PHARMACOTHERAPY

Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of Treatment: Results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1)

(2012) I. Raz et al.   DIABETES CARE

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

(2012) V. A. Fonseca et al.   DIABETES CARE

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis

(2012) C. F. Deacon et al.   DIABETES OBESITY & METABOLISM

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)

(2012) Y. Seino et al.   DIABETES OBESITY & METABOLISM

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study

(2012) G. Grunberger et al.   DIABETIC MEDICINE

Efficacy and Safety of Taspoglutide in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Plus Pioglitazone over 24 Weeks: T-Emerge 3 Trial

(2012) Robert R. Henry et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

(2012) John B Buse et al.   LANCET

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

(2012) Juris J. Meier   Nature Reviews Endocrinology

Targeting the glucagon receptor family for diabetes and obesity therapy

(2012) Young Min Cho et al.   PHARMACOLOGY & THERAPEUTICS

Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial)

(2012) Richard M. Bergenstal et al.   Diabetes Therapy

GLP-1 receptor agonists and HBA1ctarget of

(2011) K. Esposito et al.   CURRENT MEDICAL RESEARCH AND OPINION

The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study

(2011) G. E. Umpierrez et al.   DIABETES OBESITY & METABOLISM

Effects of Exenatide Plus Rosiglitazone on  -Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin

(2010) R. A. DeFronzo et al.   DIABETES CARE

A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin

(2010) J. Liutkus et al.   DIABETES OBESITY & METABOLISM

Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes

(2010) M. J. Davies et al.   DIABETES OBESITY & METABOLISM

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

(2010) R. E. Ratner et al.   DIABETIC MEDICINE

Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks

(2010) Takashi Kadowaki et al.   Journal of Diabetes Investigation

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

(2009) B. Zinman et al.   DIABETES CARE

Exenatide: a review from pharmacology to clinical practice

(2009) R. Gentilella et al.   DIABETES OBESITY & METABOLISM

Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes

(2009) K. Kaku et al.   DIABETES OBESITY & METABOLISM

Exenatide Exhibits Dose-Dependent Effects on Glycemic Control over 12 Weeks in Japanese Patients with Suboptimally Controlled Type 2 Diabetes

(2009) Takashi KADOWAKI et al.   ENDOCRINE JOURNAL

Diabetes in Asia

(2009) Juliana C. N. Chan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study

(2008) T MORETTO et al.   CLINICAL THERAPEUTICS

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

(2008) Ralph A. DeFronzo et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea

(2008) Yan Gao et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET